Bryceson AD - Search Results

1

Efficacy and tolerability of miltefosine for childhood visceral leishmaniasis in India.

Bhattacharya SK, Jha TK, Sundar S, Thakur CP, Engel J, Sindermann H, Junge K, Karbwang J, Bryceson AD, Berman JD. Bhattacharya SK, et al. Among authors: bryceson ad. Clin Infect Dis. 2004 Jan 15;38(2):217-21. doi: 10.1086/380638. Epub 2003 Dec 18. Clin Infect Dis. 2004. PMID: 14699453 Clinical Trial.

2

Oral miltefosine for Indian visceral leishmaniasis.

Sundar S, Jha TK, Thakur CP, Engel J, Sindermann H, Fischer C, Junge K, Bryceson A, Berman J. Sundar S, et al. N Engl J Med. 2002 Nov 28;347(22):1739-46. doi: 10.1056/NEJMoa021556. N Engl J Med. 2002. PMID: 12456849 Free article. Clinical Trial.

3

Miltefosine: issues to be addressed in the future.

Berman J, Bryceson AD, Croft S, Engel J, Gutteridge W, Karbwang J, Sindermann H, Soto J, Sundar S, Urbina JA. Berman J, et al. Among authors: bryceson ad. Trans R Soc Trop Med Hyg. 2006 Dec;100 Suppl 1:S41-4. doi: 10.1016/j.trstmh.2006.02.009. Epub 2006 Jun 5. Trans R Soc Trop Med Hyg. 2006. PMID: 16750231 Review.

4

Miltefosine in visceral leishmaniasis.

Olliaro PL, Ridley RG, Engel J, Sindermann H, Bryceson AD. Olliaro PL, et al. Among authors: bryceson ad. Lancet Infect Dis. 2003 Feb;3(2):70. doi: 10.1016/s1473-3099(03)00512-7. Lancet Infect Dis. 2003. PMID: 12560189 No abstract available.

5

Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda.

Guerin PJ, Olliaro P, Sundar S, Boelaert M, Croft SL, Desjeux P, Wasunna MK, Bryceson AD. Guerin PJ, et al. Among authors: bryceson ad. Lancet Infect Dis. 2002 Aug;2(8):494-501. doi: 10.1016/s1473-3099(02)00347-x. Lancet Infect Dis. 2002. PMID: 12150849 Review.

6

Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries.

Berman JD, Badaro R, Thakur CP, Wasunna KM, Behbehani K, Davidson R, Kuzoe F, Pang L, Weerasuriya K, Bryceson AD. Berman JD, et al. Among authors: bryceson ad. Bull World Health Organ. 1998;76(1):25-32. Bull World Health Organ. 1998. PMID: 9615494 Free PMC article. Clinical Trial.

7

Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome).

Davidson RN, di Martino L, Gradoni L, Giacchino R, Gaeta GB, Pempinello R, Scotti S, Cascio A, Castagnola E, Maisto A, Gramiccia M, di Caprio D, Wilkinson RJ, Bryceson AD. Davidson RN, et al. Among authors: bryceson ad. Clin Infect Dis. 1996 Jun;22(6):938-43. doi: 10.1093/clinids/22.6.938. Clin Infect Dis. 1996. PMID: 8783690 Clinical Trial.

8

A comparison of three dosage regimens of sodium stibogluconate in the treatment of visceral leishmaniasis in Kenya.

Chulay JD, Bhatt SM, Muigai R, Ho M, Gachihi G, Were JB, Chunge C, Bryceson AD. Chulay JD, et al. Among authors: bryceson ad. J Infect Dis. 1983 Jul;148(1):148-55. doi: 10.1093/infdis/148.1.148. J Infect Dis. 1983. PMID: 6309993 Clinical Trial.

9

Epidemic visceral leishmaniasis in Sudan: a randomized trial of aminosidine plus sodium stibogluconate versus sodium stibogluconate alone.

Seaman J, Pryce D, Sondorp HE, Moody A, Bryceson AD, Davidson RN. Seaman J, et al. Among authors: bryceson ad. J Infect Dis. 1993 Sep;168(3):715-20. doi: 10.1093/infdis/168.3.715. J Infect Dis. 1993. PMID: 8394861 Clinical Trial.

10

Visceral leishmaniasis in India.

Bryceson A. Bryceson A. Lancet. 2000 Dec 2;356(9245):1933. doi: 10.1016/S0140-6736(05)73486-3. Lancet. 2000. PMID: 11130411 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

145 results

Search Page